Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Azitra, Inc. stock logo
AZTR
Azitra
$0.75
-18.9%
$1.41
$0.73
$4.98
$3.26M-1.622.08 million shs2.05 million shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.20
$0.17
$2.96
$13M-25.98N/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
$1.26
-6.7%
$1.45
$0.65
$17.00
$22.97M1.19360,040 shs482,116 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$2.30
-0.4%
$2.81
$1.29
$7.12
$12.12M2.245,923 shs25,369 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Azitra, Inc. stock logo
AZTR
Azitra
0.00%-13.08%-35.79%-51.68%-80.47%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%0.00%0.00%-60.96%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
0.00%+1.50%-19.16%+92.03%-90.92%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00%-11.47%-16.19%+23.30%-18.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Azitra, Inc. stock logo
AZTR
Azitra
1.7251 of 5 stars
0.05.00.00.03.30.01.3
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.5447 of 5 stars
3.34.00.00.01.10.81.3
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.4805 of 5 stars
0.05.00.00.01.50.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Azitra, Inc. stock logo
AZTR
Azitra
0.00
N/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2.50
Moderate Buy$53.004,106.35% Upside
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AZTR, IMCC, CTXR, and CHHE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/13/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/30/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
6/9/2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Azitra, Inc. stock logo
AZTR
Azitra
$10K264.43N/AN/A$4.97 per share0.15
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/AN/AN/ANaN
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/A$10.25 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.44M0.31N/AN/A$1.03 per share2.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Azitra, Inc. stock logo
AZTR
Azitra
-$8.97MN/A0.00N/AN/AN/A-183.57%-138.65%11/11/2025 (Estimated)
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$39.14MN/A0.001.01N/AN/A-60.03%-33.83%N/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)

Latest AZTR, IMCC, CTXR, and CHHE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q3 2025
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million
8/12/2025Q2 2025
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Azitra, Inc. stock logo
AZTR
Azitra
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Azitra, Inc. stock logo
AZTR
Azitra
N/A
1.24
1.24
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
N/A
0.47
0.14
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
0.32
0.72
0.62

Institutional Ownership

CompanyInstitutional Ownership
Azitra, Inc. stock logo
AZTR
Azitra
11.16%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/A
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
16.88%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%

Insider Ownership

CompanyInsider Ownership
Azitra, Inc. stock logo
AZTR
Azitra
0.25%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
31.30%
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
10.70%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Azitra, Inc. stock logo
AZTR
Azitra
103.53 million3.52 millionNot Optionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
Citius Pharmaceuticals, Inc. stock logo
CTXR
Citius Pharmaceuticals
2017.01 million15.19 millionOptionable
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
3405.25 millionN/ANot Optionable

Recent News About These Companies

IM Cannabis (NASDAQ:IMCC) Rating Lowered to Hold at Wall Street Zen
IM Cannabis Provides Corporate Updates
CSE Bulletin: Delist - IM Cannabis Corp. (IMCC)
IM Cannabis Provides Corporate Updates

New MarketBeat Followers Over Time

Media Sentiment Over Time

Azitra stock logo

Azitra NYSEAMERICAN:AZTR

$0.75 -0.17 (-18.87%)
Closing price 04:10 PM Eastern
Extended Trading
$0.76 +0.01 (+0.79%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

Citius Pharmaceuticals stock logo

Citius Pharmaceuticals NASDAQ:CTXR

$1.26 -0.09 (-6.67%)
Closing price 04:00 PM Eastern
Extended Trading
$1.27 +0.01 (+0.79%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$2.30 -0.01 (-0.43%)
Closing price 03:59 PM Eastern
Extended Trading
$2.19 -0.11 (-4.57%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.